Gallium-68 in Medical Diagnostics

Positron Emission Tomography (PET) scans generate images of the body making noninvasive diagnostics possible for thousands of cancer patients. To provide higher image quality that better establishes and locates malignancies, ensuring more accurate and precise diagnoses, scientists continually develop new radiotracers. Gallium-68-based radiotracers have demonstrated promising clinical applications. However, predicting successful implementation in clinical practice requires a cost-benefit comparison against existing radiotracers such as fluorine-18-based radiopharmaceuticals. This presentation examines the imaging advantages and cost-effectiveness of gallium-68-based radiotracers against other conventional radiotracers and imaging modalities to assess when gallium-68 PET diagnostics would be beneficial in clinical settings.